-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O2.6 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, artificial intelligence (AI), Fundamental Science, clinical trials, adult, Translational Research, Plasma Cell Disorders, genomics, bioinformatics, Combination therapy, Clinical Research, Diseases, patient-reported outcomes, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, Study Population, Human, pathogenesis, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Sunday, December 11, 2022: 4:30 PM-6:00 PM
New Orleans Theater C (Ernest N. Morial Convention Center)
Moderators:
Natalia Neparidze, MD, Yale University School of Medicine and Yale Cancer Center and Aurore Perrot, MD, PhD, CHU de Toulouse, IUCT-O, Université de Toulouse
Disclosures:
Neparidze: GSK: Research Funding; Janssen: Research Funding. Perrot: Abbvie: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.
This session will highlight recent efforts at refining and improving prognostic assessments in Multiple Myeloma. Dr. Cirrincione will present the genomic data suggesting alternative, previously unknown myeloma-initiating events paving the way toward further exploration of large datasets with novel analytical methods. Dr. Kaiser will present data on the utility of extended genetic profiling based on the meta-analysis of molecular events from several randomized clinical trials. Dr. Poletti will focus on defining a novel methodological framework aimed at the identification of copy-number signatures and their biological significance in myeloma. Dr. Maura will describe the first artificial intelligence prediction model for newly diagnosed multiple myeloma (NDMM) to guide individual treatment decisions. Dr. Terpos will highlight the role of next-generation flow cytometry assessment of circulating tumor cells as a potential independent prognostic marker for risk stratification for NDMM. Dr. Hofste op Bruinink will present the study evaluating combination of plasma cell leukemia-like status with the R2-ISS classification to improve prognostic accuracy in high-risk NDMM.
4:30 PM

Anthony Cirrincione, PhD1*, Bachisio Ziccheddu, PhD1*, Kylee H Maclachlan, MBBCh, PhD2, Alexandra M. Poos, PhD3*, Monika Chojnacka, BS1, Benjamin Diamond, MD1, Eileen M Boyle, MD, PhD4, Patrick Blaney, MS4*, Dylan Gagler, MS4*, Yanming Zhang5*, Ahmet Dogan, MD, PhD6, Alexander M Lesokhin, MD2, Faith E. Davies, MD4*, Neha Korde, MD7, Marc S Raab, MD3*, Niels Weinhold, PhD3*, Saad Usmani, MD2, Gareth J. Morgan, MD4, Ola Landgren, MD1 and Francesco Maura, MD8

1Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
3Multiple Myeloma Research Group, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
4Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, NY
5Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY
6Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY
8Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL

4:45 PM

Martin F. Kaiser, MD, FRCP, FRCPath1,2, Pieter Sonneveld, MD3, David Cairns, PhD4*, Marc S Raab, MD5*, Alessandra Larocca, MD, PhD6, Sarah R Brown, PhD, MSc, BSc4*, Marc-A. Baertsch, MD7*, Cong Li, PhD8*, Pellegrino Musto, MD9, Kwee Yong10*, Elias K Mai, MD11*, Andrea Capra12*, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath4*, Hartmut Goldschmidt, MD11,13, Mario Boccadoro, MD14, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM15, Niels Weinhold, PhD11* and Francesca Gay, MD, PhD16*

1The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
2Myeloma Molecular Therapy Group, The Institute of Cancer Research, London, United Kingdom
3Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
4Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
5Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
6Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
7Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
8Takeda Development Center Americas, Inc, Deerfield, IL
9Hematology Section, Department of Emergency and Transplantation, University of Bari Medical School, Bari, Italy
10Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
11Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
12Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-, Torino, ITA
13National Center for Tumor Diseases (NCT), Heidelberg, Germany
14Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
15Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom
16Division of Hematology, University of Torino, Torino, Italy

5:00 PM

Andrea Poletti, MSc1*, Stafano Delle Vedove, MSc1*, Gaia Mazzocchetti1*, Vincenza Solli1,2*, Ajsi Kanapari, MSc1*, Enrica Borsi1*, Marina Martello1*, Giovanni Martinelli, MD3,4, Silvia Armuzzi1*, Ilaria Vigliotta5*, Barbara Taurisano, MSc1*, Ignazia Pistis5*, Elena Zamagni1,5*, Michele Cavo, MD1,5* and Carolina Terragna, PhD1,5*

1"Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
2Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
3Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
4University of Bologna, Meldola, Italy
5Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

5:15 PM

Francesco Maura, MD1, Arjun Raj Rajanna, MSc1*, Andriy Derkach, PhD2*, Bachisio Ziccheddu, PhD3*, Niels Weinhold, PhD4*, Kylee H Maclachlan, MBBCh, PhD5, Benjamin Diamond1*, Faith E. Davies, MD6*, Eileen Boyle6*, Brian A. Walker, PhD7, Alexandra M Poos, PhD4*, Malin Hultcrantz, MD, PhD5, Ariosto Siqueira Silva, PhD8*, Oliver Hampton, PhD9*, Jamie Teer, PhD8*, Niccolo Bolli, MD10*, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM11, Martin F. Kaiser, MD, FRCP, FRCPath12, Charlotte Pawlyn, PhD13, Gordon Cook14*, Dennis Verducci1*, Dickran Kazandjian, MD1, Frits van Rhee15, Saad Usmani, MD16, Ken H. Shain, MD, PhD8, Marc S Raab, MD4*, Gareth J. Morgan, MD6 and Ola Landgren, MD3

1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
3Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
4Multiple Myeloma Research Group, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
5Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
6NYU Langone, Perlmutter Cancer Center, New York
7Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
8Department of Malignant Hematology, Moffitt Cancer Center, Tampa
9M2GEN, Tampa, FL
10Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico & University of Milan, Milan, Italy
11Department of Haematology, NCCC Freeman Road Hospital, Newcastle Upon Tyne, United Kingdom
12The Institute of Cancer Research, London, ENG, United Kingdom
13The Institute of Cancer Research, London, United Kingdom
14Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
15Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
16Myeloma Service, Memorial Sloan Kettering Cancer Center, New York

5:30 PM

Ioannis V Kostopoulos, PhD1*, Panagiotis Malandrakis, MD2*, Ioannis Ntanasis-Stathopoulos, MD3*, Pantelis Roussakis, MSc1*, Evangelos Eleutherakis Papaiakovou, MD3*, Chrysanthi Panteli1*, Nikolaos Angelis1*, Nikolaos Kanellias, MD3*, Nikolaos Orologas-Stavrou1*, Foteini Theodorakakou, MD2*, Despina Fotiou, MD3*, Magdalini Migkou, MD3*, Maria Gavriatopoulou, MD3*, Efstathios Kastritis, MD3*, Ourania E. Tsitsilonis, MD, PhD1*, Meletios-Athanasios Dimopoulos, MD, PhD4 and Evangelos Terpos, MD, PhD3

1Department of Biology, National and Kapodistrian University of Athens, School of Science, Athens, Greece
2Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
3Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4Plasma Cell Dyscrasias Unit, Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

5:45 PM

Davine Hofste op Bruinink, MD, MSc1,2*, Rowan Kuiper, PhD1,3*, Mark van Duin, PhD1*, Tom Cupedo, PhD1*, Vincent H.J. van der Velden, PhD2*, Remco Hoogenboezem, MSc1*, Bronno van der Holt, PhD4*, Berna Beverloo, PhD5*, Erik T. Valent, PhD3*, Michael Vermeulen, BSc1*, Mattia D'Agostino, MD6*, Francesca Gay, MD, PhD6*, Annemiek Broijl, MD, PhD1*, Herve Avet-Loiseau, MD, PhD7*, Nikhil C Munshi, MD, PhD8, Pellegrino Musto, MD9, Philippe Moreau, MD10*, Sonja Zweegman, MD, PhD11, Niels W.C.J. van de Donk, MD, PhD11 and Pieter Sonneveld, MD1

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
3SkylineDx, Rotterdam, Netherlands
4HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
5Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands
6Division of Hematology, University of Torino, Torino, Italy
7Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
8Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9Hematology and Stem Cell Transplantation Unit - A.O.U. Consorziale Policlinico di Bari, Bari, Italy
10Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
11Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands

*signifies non-member of ASH